TrialThe Journal of dermatology2021

A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.

Hiroo Yokozeki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.